English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 18 September 2019, 20:40 HKT/SGT
Share:
    

Source: Eisai
Eisai Selected for Membership in Dow Jones Sustainability Asia Pacific Index 2019

TOKYO, Sept 18, 2019 - (JCN Newswire) - Eisai Co., Ltd. has been selected for a membership in the Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific), the Asia Pacific version of the Dow Jones Sustainability Indices (DJSI), which are a family of premier global indices for socially responsible investment (SRI). This marks Eisai's sixth selection.

The DJSI family was jointly established between RobecoSAM AG (Switzerland) and S&P Dow Jones Indices LLC (United States) in 1999 and assesses the corporate sustainability performance of eligible member companies based on economic, environmental and social criteria. The DJSI is one of the important investment criteria for the investors around the world who emphasize on corporate initiatives for improving non-financial value focused on environmental, social, and governance (ESG).

This year, the DJSI Asia Pacific has selected top 148 companies (76 of which are from Japan) from among the approximate major600 companies in the region. Eisai received high scores in categories such as Innovation Management, Cost Burden Addressing, Environment Policy and Management Systems, Product Quality and Recall Management as well as Human Rights.

In addition to the DJSI Asia Pacific, Eisai has been selected for the FTSE4Good Index Series, which isanother global benchmark SRI index as well as for the MSCI Japan Empowering Women Index (WIN), the FTSE Blossom Japan Index, the MSCI Japan ESG Select Leaders Index and S&P/JPX Carbon Efficient Index, which are the four ESG investment indices for Japanese stocks adopted by the Government Pension Investment Fund (GPIF).Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. By strengthening its ESG initiatives and increasing non-financial value, Eisai is striving to sustainably enhance corporate value based on this corporate philosophy.

About Eisai

Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com

Contact:
Public Relations Department
Eisai Co., Ltd.
+81-(0)3-3817-5120


Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Eisai Releated News
July 1, 2020 13:02 HKT/SGT
Remap-Cap to Partner With Eisai on Innovative Trial to Combat COVID
July 1, 2020 09:00 HKT/SGT
GCARとエーザイ、中等度から重度のCOVID-19感染患者様に対する治療薬創出を目指す革新的アダプティブデザインによる臨床試験(REMAP-COVID)を開始
June 25, 2020 10:47 HKT/SGT
Eisai Receives Approval for Parkinson's Disease Treatment Equfina in South Korea
June 25, 2020 10:00 HKT/SGT
エーザイ、パーキンソン病治療剤「エクフィナ(R)」(一般名:サフィナミドメシル酸塩)が韓国において承認を取得
June 23, 2020 16:00 HKT/SGT
エーザイ、新株予約権証券の発行登録書の提出について
More news >>
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575